Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
08/2003
08/14/2003WO2003066666A2 Compositions and methods for treatment of vitamin d deficiency
08/14/2003WO2003066636A1 Inhibitors of alpha l beta 2 integrin mediated cell adhesion
08/14/2003WO2003066635A1 Piperidine derivatives
08/14/2003WO2003066634A1 Substituted fused pyrazolecarboxylic acid arylamides and related compounds
08/14/2003WO2003066632A1 Sulphonyl compounds with 5 -ht6 receptor affinity
08/14/2003WO2003066630A2 Quinolinone derivatives for treating cell proliferation related disorders
08/14/2003WO2003066629A2 Heteroaryl compounds useful as inhibitors of gsk-3
08/14/2003WO2003066623A1 Dihydrobenzodiazepin-2-one derivatives for the treatment of neurological disorders
08/14/2003WO2003066621A1 Piperidine derivatives and their use as antagonists of tachykinins
08/14/2003WO2003066620A1 Dihydro-thia-phenanthrene-carbonyl-guanidines, method for the production thereof, use thereof as a medicament or diagnostic reagent
08/14/2003WO2003066618A1 Cytoprotective benzofuran derivatives
08/14/2003WO2003066608A1 Catechol bioisosteres
08/14/2003WO2003066604A2 Novel aryl- and heteroarylpiperazines
08/14/2003WO2003066599A1 N-allyloxyethyl-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocines and the use of the same as pharmaceuticals
08/14/2003WO2003066596A1 Pyridineamido derivatives as inhibitors of monoamine oxidase (mao-b)
08/14/2003WO2003066595A2 2 - piperazine - pyridines useful for treating pain
08/14/2003WO2003066594A2 3-alkanoylamino-propionic acid derivatives used as inhibitors of integrin avss6
08/14/2003WO2003066592A1 Gamma secretase inhibitors
08/14/2003WO2003066591A1 Piperidine derivative compounds and drugs containing the compounds as the active ingredient
08/14/2003WO2003066590A1 Piperidine derivative compounds and drugs containing the compounds as the active ingredient
08/14/2003WO2003066589A1 Piperidylcarboxamide derivatives and their use in the treatment of tachykinim-mediated diseases
08/14/2003WO2003066579A2 Novel bicyclic hydroxamates as inhibitors of histone deacetylase
08/14/2003WO2003066577A1 N-biphenylmethyl aminocycloalkanecarboxamide derivatives with a substiituent on the methyl useful as bradykinin antagonists
08/14/2003WO2003066165A1 Tumor necrosis factor combined with interferon in demyelinating diseases
08/14/2003WO2003066099A1 2,4,6-triamino-1,3,5-triazine derivative
08/14/2003WO2003066091A2 Compositions and methods for modulation of effects on phagocyte and lymphoid cell populations employing tirc7
08/14/2003WO2003066084A1 Use of glp-1 compound for treatment of critically ill patients
08/14/2003WO2003066077A2 Diagnostics and therapeutics for diseases associated with neuromedin u1 receptor (nmu1)
08/14/2003WO2003066071A1 Formulations comprising psychotropic drugs and selenium
08/14/2003WO2003066067A2 Use of co-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases
08/14/2003WO2003066065A1 Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds
08/14/2003WO2003066059A1 Treatment of neuroblastoma
08/14/2003WO2003066056A1 Method of promoting neuronal growth
08/14/2003WO2003066050A1 Opioid receptor active 4-(3-hydroxyphenyl) or 4-(3-alkoxyphenyl)-1,2,4-triazole compounds
08/14/2003WO2003066047A1 Use of indole-3-acetic acids in the treatment of asthma, copd and other diseases
08/14/2003WO2003066041A1 Carnitine in the treatment of geriatric depression
08/14/2003WO2003066040A1 Medicinal compositions containing gabapentin or pregabalin and n-type calcium channel antagonist
08/14/2003WO2003066037A1 Spermidine derivatives for the treatment of chronic neurodegenerative diseases
08/14/2003WO2003066030A2 Pharmaceutical tablet
08/14/2003WO2003066005A2 Ansamycins having improved pharmacological and biological properties
08/14/2003WO2003066004A2 Therapeutic compounds
08/14/2003WO2003066003A2 Anti-pathogen treatements
08/14/2003WO2003065999A2 Proliferated cell lines and uses thereof
08/14/2003WO2003065994A2 Schwann cell and phosphodiesterase inhibitors based therapy
08/14/2003WO2003065989A2 (oxime)carbamoyl fatty acid amide hydrolase inhibitors
08/14/2003WO2003065987A2 Granzyme b inhibitors
08/14/2003WO2003065983A2 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
08/14/2003WO2003065971A2 Non-myeloablative tolerogenic treatment with tyrphostins
08/14/2003WO2003055438A3 Crystalline form i of 2-methyl-4-(4-methyl-1-piperazinyl) 10h thieno [2,3-b][1,5]benzodiazepine
08/14/2003WO2003053941A3 Barbituric acid derivatives as inhibitors of tnf-alpha converting enzyme (tace) and/or matrix metalloproteinases
08/14/2003WO2003045437A8 Pharmaceutical compositions of 5,7,14-triazatetracyclo[10.3.1.0(2,11).0(4,9)]-hexadeca-2(11)3,5,7,9-pentaene
08/14/2003WO2003037335A8 5-heteroatom-substituted pyrazoles
08/14/2003WO2003032973A3 Composition comprising paracetamol and a bitterness masking component
08/14/2003WO2003031568A8 Intracellular signaling molecules
08/14/2003WO2003031416A3 [[2-(amino-3,4-dioxo-1cyclobuten-1-yl)amino]alkyl]-acid derivatives for the treatment of pain
08/14/2003WO2003029433A3 Chimeric viral vectors for gene therapy
08/14/2003WO2003024955A3 Small molecule inhibitors of caspases
08/14/2003WO2003015699A3 Topical compositions and methods for treating pain
08/14/2003WO2003013655A3 Carbonic anhydrase inhibitors
08/14/2003WO2002101048A3 NEW POLYNUCLEOTIDES AND POLYPEPTIDES OF THE IFNα-7 GENE
08/14/2003WO2002081430A3 Novel benzylideneamino guanidines and their uses as ligands to the melanocortin receptors
08/14/2003WO2002064083A3 Synthesis of 3-amino-thalidomide and its enantiomers
08/14/2003WO2002058626A3 Methods and compositions for the identification and treatment of neurodegenerative disorders
08/14/2003WO2002057453A3 Polypetides and nucleic acids encoding same
08/14/2003WO2002051438A3 Use of repulsive guidance molecule (rgm) and its modulators
08/14/2003WO2002038601A3 Foggy
08/14/2003WO2002038142A3 Serotonergic compositions and methods for treatment of mild cognitive impairment
08/14/2003WO2002029055A3 Carbohydrate-associated proteins
08/14/2003WO2002016584A3 Process for the preparation of neutrophil inhibitory factor
08/14/2003WO2002015933A3 Combination comprising an at1-receptor antagonist and an insulin secretion enhancer or an insulin sensitiser
08/14/2003WO2002014351A3 α7 NICOTINIC RECEPTOR PEPTIDES AS LIGANDS FOR β AMYLOID P EPTIDES
08/14/2003WO2002011714A3 Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
08/14/2003WO2001092527A3 Regulators of apoptosis
08/14/2003WO2001090148A3 Neurotransmitter transporters
08/14/2003US20030153774 Process for the preparation of citalopram
08/14/2003US20030153621 Administering mixtures of 13-hydroxyoctadeca-9Z,11E-dienoic acid (13-HODE) and carriers comprising glycerides or fatty esters as controllers of endothelial growth factors
08/14/2003US20030153613 Hypotensive agents for eye, using an aclurea indole compounds, potassium channel blockers; glaucoma
08/14/2003US20030153610 Substituted oxazolidinones and their in the field of blood coagulation
08/14/2003US20030153605 Enzyme inhibitors of nitric oxide synthase
08/14/2003US20030153599 Chroman and benzofuran derivatives as 5-hydroxytryptamine-6 ligands
08/14/2003US20030153596 Novel thiourea derivatives and the pharmaceutical compositions containing the same
08/14/2003US20030153595 Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
08/14/2003US20030153592 Method
08/14/2003US20030153590 Method of treating alcoholism or alcohol abuse
08/14/2003US20030153588 Such as N-butyl-2-(4-(4-chloro-3-methoxyphenyl)-5-pyridin-4-yl-1H-imidazole-2 -yl)isobutylamide for treatment of neurotraumatic disorders
08/14/2003US20030153587 Such as 3-((3-bromo-4-hydroxyphenyl)methyl)-5-ethyl-7,8-dihydro-2-(tetrahydro-2H -pyran-4-yl)amino)-3H-imidazo(2,1-b) purin-4(5H)-one for treating sexual disorders
08/14/2003US20030153576 Such as amino-indazoles for treatment of central nervous system disorders
08/14/2003US20030153574 Such as 4-(Benzoxazol-2-yl)-1,4-diazabicyclo(3.2.2)nonane hydrobromide which stimulates nicotinic receptors
08/14/2003US20030153569 Novel pyrazole and pyrazoline substituted compounds
08/14/2003US20030153568 Serine/threonine and tyrosine kinases inhibitors
08/14/2003US20030153566 Adenosine receptor agonist
08/14/2003US20030153563 CRF receptor antagonists and methods relating thereto
08/14/2003US20030153562 Cognition activators
08/14/2003US20030153559 Treatment of an oxygen and/or energy deficit; a poly(adenosine diphosphate ribose)-polymerase inhibitor; treating autoimmune, neurodegenerative and diseases caused by a toxic effect; viricides
08/14/2003US20030153558 Immunomodulators and/or inhibiting cytokine release
08/14/2003US20030153536 Compounds and methods of treating transplant rejection
08/14/2003US20030153530 Solubility enhancing component other than a cyclodextrin, particularly a polyanionic component, an oxy-chloro component to aid in preserving the composition, liquid carrier
08/14/2003US20030153525 Identifies differential expression of 1465, 1587, 2146, 2207, 32838, 336 OR 52908 genes in tissues relating to pain sensation relative to their expression in normal or non-painful disease states
08/14/2003US20030153523 Screening library of test compounds, each of which is attached to a solid support, with a dye-labeled RNA molecule to form a dye-labeled target RNA:support-attached test compound complex
08/14/2003US20030153518 Activation and inhibition of the immune system
1 ... 1183 1184 1185 1186 1187 1188 1189 1190 1191 1192 1193 1194 1195 1196 1197 1198 1199 1200 1201 1202 1203 ... 1833